4//SEC Filing
Drutz David 4
Accession 0001104659-22-120752
CIK 0001326190other
Filed
Nov 20, 7:00 PM ET
Accepted
Nov 21, 4:05 PM ET
Size
8.2 KB
Accession
0001104659-22-120752
Insider Transaction Report
Form 4
Drutz David
Director
Transactions
- Exercise/Conversion
Common Stock, par value $0.0001
2022-11-18$2.40/sh+139$334→ 20,151 total - Exercise/Conversion
Stock Options (option to buy)
2022-11-18−139→ 0 totalExercise: $2.40Exp: 2022-12-31→ Common Stock, par value $0.0001 (139 underlying)
Holdings
- 333(indirect: See Footnote)
Common Stock, par value $0.0001
Footnotes (3)
- [F1]Represents Common Stock held by Pacific Biopharma Associates, LLC, of which the reporting person is the President.
- [F2]This option was previously reported as covering 4,178 shares at an exercise price of $0.08 per share, but was adjusted to reflect a one-for-thirty reverse stock split that occurred on September 13, 2018.
- [F3]This option is fully vested and exercisable as of the date hereof.
Documents
Issuer
Altimmune, Inc.
CIK 0001326190
Entity typeother
Related Parties
1- filerCIK 0001428764
Filing Metadata
- Form type
- 4
- Filed
- Nov 20, 7:00 PM ET
- Accepted
- Nov 21, 4:05 PM ET
- Size
- 8.2 KB